Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis

Ear, Nose and Throat Journal

Volumn 87, Issue 6, 2008, Pages 340-353

  Patel, Piyush ^a   Patel, Deepen ^a   Kunjibettu, Sudeesha ^b   Hall, Nancy ^b   Wingertzahn, Mark A ^b  

^a Allied Research International   (Canada)

^b ALTANA Pharma US   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; PLACEBO; RAGWEED ANTIGEN; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENVIRONMENTAL EXPOSURE; EPISTAXIS; FEMALE; HEADACHE; HUMAN; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; RAGWEED; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; ADOLESCENT; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HAY FEVER; HOSPITALIZATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREGNENEDIONES; REFERENCE VALUES; RHINITIS, ALLERGIC, SEASONAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 46849096527     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130808700612     Document Type: Article

References (25)

1. Lebel B, Bousquet J, Morel A, et al. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988; 82 ( 5 Pt 1 ): 869-77.
2. Food and Drug Administration. Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Rockville Md. :Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 2000.
3. Ouraishi SA, Davies MJ, Craig TJ. Inflammatory responses in allergic rhinitis: Traditional approaches and novel treatment strategies. J Am Osteopath Assoc 2004; 104 ( 5 Suppl 5 ): S7-S15.
4. Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol 2004; 114 ( 5 Suppl ): S146-S153.
5. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 1998; 317 ( 7173 ): 1624-9.
6. Day JH, Briscoe MP. Environmental exposure unit: A system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999; 83 ( 2 ): 83-89 quiz 89-93.
7. Day JH, Briscoe MP, Rafeiro F, et al. Onset of action of intranasal budesonide ( Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 2000; 105 ( 3 ): 489-94.
8. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999; 20 ( 3 ): 167-72.
9. Nave R, Wingertzahn MA, Brookman S, et al. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 2006; 46 ( 4 ): 461-7.
10. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 118 ( 5 ): 1142-8.
11. Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007; 98 ( 2 ): 175-81.
12. Chervinsky P. Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007; 99 ( 1 ): 69-76.
13. Dietzel K, Engelstätter R, Keller A. Ciclesonide: An on-site-activated steroid. In: Hansel TT, Barnes PJ, eds. New Drugs for Asthma, Allergy and COPD. Progress in Respiratory Research.Vol. 31. Basel Switzerland:Karger; 2001:91-3.
14. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. PuIm Pharmacol Ther 2005; 18 ( 6 ): 390-6.
15. Nasonex [ package insert]. Kenilworth N.J.:Schering; 2005.
16. Rhinocort Aqua [package insert]. Wilmington Del.:AstraZeneca; 2004.
17. Flonase [package insert]. Research Triangle Park N.C.:Glaxo-SmithKline; 2004.
18. Nasacort AQ [ package insert]. Bridgewater N.J.:Aventis Pharmaceuticals; 2004.
19. Stübner P. Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: Randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004; 20 ( 6 ): 891-902.
20. Mygind N, Nielsen LP, Hoffmann HJ, et al. Mode of action of intranasal coiticosteroids. J Allergy Clin Immunol 2001; 108 ( 1 Suppl ): S16-S25.
21. Wingeitzahn MA, Takanashi K, Nagano A, et al. Persistence and effusion clearance to esophagus of ciclesonide in hypotonic and isotonic suspensions [abstract]. J Allergy Clin Immunol 2006; 117 ( 2 Suppl ): S260.
22. Wingeitzahn MA, Sato H, Nave R. Comparison of nasal tissue concentrations in rabbits following administration of hypotonic and isotonic ciclesonide suspensions [abstract]. J Allergy Clin Immunol 2005; 115 ( 2 Suppl ): S126.
23. Seidenari S, Di Nardo A, Mantovani L, Giannetti A. Parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical corticosteroids. Exp Dermatol 1997; 6 ( 2 ): 75-80.
24. Pershing LK, Silver BS, Krueger GG, et al. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm Res 1992; 9 ( 1 ): 45-51.
25. Masuyama K, Till SJ, Jacobson MR, et al. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids. J Allergy Clin Immunol 1998; 102 ( 4 Pt 1 ): 610-17.